ACOR News and Press, Acorda Therapeutics Inc. From 01/04/22

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, MD, President and CEO, will present at the H.C. Wainwright BIOCONNECT Virtual Conference, taking place from January 10 – 13, 2022. H.C. Wainwright BIOCONNECT Conference Date: January 10 – 13...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that John Varian has joined its board of directors, effective January 1, 2022. “We are delighted that John has joined Acorda’s board of directors,” said Ron Cohen, M.D., Acorda’s President and Chief...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Acorda Therapeutics, Inc. (ACOR) Q3 2021 Earnings Conference Call Nov 09, 2021 04:30 PM ET Company Participants Tierney Saccavino - Executive Vice President-Corporate Communications Ron Cohen - Chief Executive Officer Mike Gesser - Chief Financial Officer Conference Call Participants Presenta...

Acorda Therapeutics (NASDAQ:ACOR): Q3 Non-GAAP EPS of -$1.43 beats by $0.13; GAAP EPS of -$2.43 misses by $0.87. Revenue of $31.46M (-40.7% Y/Y) beats by $0.89M. Shares +9.3%. Press Release For further details see: Acorda Therapeutics EPS beats by $0.13, beats on revenue

€5 million upfront payment Significant double-digit percent of selling price for supply Additional sales-based milestones Commercial launch expected mid-2022 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a Webcast in conjunction with its third quarter 2021 update and financial results on Tuesday, November 9, at 4:30 p.m. ET. To participate in the Webcast, please use the following pre-registration link: https://event.on24.com...